SANA Quote, Financials, Valuation and Earnings

Editas Medicine, Inc. has a net margin of -- compared to Sana Biotechnology, Inc.'s net margin of -332.98%. Sana Biotechnology, Inc.'s return on equity of -109.55% beat Editas Medicine, Inc.'s return on equity of -246.73%.

Sana Biotechnology, Inc. has a consensus price target of $8.57, signalling upside risk potential of 89.22%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 131.9%. Given that Editas Medicine, Inc. has higher upside potential than Sana Biotechnology, Inc., analysts believe Editas Medicine, Inc. is more attractive than Sana Biotechnology, Inc..

Sana Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.441, suggesting its more volatile than the S&P 500 by 144.07%.

Sana Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.

Sana Biotechnology, Inc. quarterly revenues are --, which are smaller than Editas Medicine, Inc. quarterly revenues of $7.5M. Sana Biotechnology, Inc.'s net income of -$42.2M is lower than Editas Medicine, Inc.'s net income of -$25.1M. Notably, Sana Biotechnology, Inc.'s price-to-earnings ratio is -- while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology, Inc. is -- versus 4.05x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -- compared to Sana Biotechnology, Inc.'s net margin of 13.85%. Sana Biotechnology, Inc.'s return on equity of -109.55% beat Illumina, Inc.'s return on equity of 30.55%.

Sana Biotechnology, Inc. has a consensus price target of $8.57, signalling upside risk potential of 89.22%. On the other hand Illumina, Inc. has an analysts' consensus of $125.28 which suggests that it could fall by -7.42%. Given that Sana Biotechnology, Inc. has higher upside potential than Illumina, Inc., analysts believe Sana Biotechnology, Inc. is more attractive than Illumina, Inc..

Sana Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

Sana Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

Sana Biotechnology, Inc. quarterly revenues are --, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Sana Biotechnology, Inc.'s net income of -$42.2M is lower than Illumina, Inc.'s net income of $150M. Notably, Sana Biotechnology, Inc.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 30.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology, Inc. is -- versus 4.97x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -- compared to Sana Biotechnology, Inc.'s net margin of -735.19%. Sana Biotechnology, Inc.'s return on equity of -109.55% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Sana Biotechnology, Inc. has a consensus price target of $8.57, signalling upside risk potential of 89.22%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 133.91%. Given that Intellia Therapeutics, Inc. has higher upside potential than Sana Biotechnology, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Sana Biotechnology, Inc..

Sana Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Sana Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Sana Biotechnology, Inc. quarterly revenues are --, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Sana Biotechnology, Inc.'s net income of -$42.2M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Sana Biotechnology, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology, Inc. is -- versus 17.47x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -- compared to Sana Biotechnology, Inc.'s net margin of -98.85%. Sana Biotechnology, Inc.'s return on equity of -109.55% beat Pacific Biosciences of California, Inc.'s return on equity of -218.65%.

Sana Biotechnology, Inc. has a consensus price target of $8.57, signalling upside risk potential of 89.22%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.36 which suggests that it could grow by 25.38%. Given that Sana Biotechnology, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Sana Biotechnology, Inc. is more attractive than Pacific Biosciences of California, Inc..

Sana Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.319, suggesting its more volatile than the S&P 500 by 131.863%.

Sana Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Sana Biotechnology, Inc. quarterly revenues are --, which are smaller than Pacific Biosciences of California, Inc. quarterly revenues of $38.4M. Sana Biotechnology, Inc.'s net income of -$42.2M is lower than Pacific Biosciences of California, Inc.'s net income of -$38M. Notably, Sana Biotechnology, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology, Inc. is -- versus 3.66x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.